-
平臺(tái)編號(hào)：bio-68790
-
國際編號(hào)：HB-8501?
-
細(xì)胞信息： SA13
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
SA13
數(shù)量：大量
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG; kappa light chain
ATCC Number：HB-8501?
運(yùn)輸方式：凍存運(yùn)輸
生長狀態(tài)：懸浮生長
是否是腫瘤細(xì)胞：0
物種來源：人
規(guī)格：0.5ml Designations: SA13
Depositors: ?Cetus Corp.
Isotype: IgG; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism:human (B cell); human (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against tetanus toxoid
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 11,12
D16S539: 11,12
D5S818: 12,13
D7S820: 9,10,12
THO1: 8,10,9.3
TPOX: 8,10,11
vWA: 16,17,20
Comments:Peripheral blood B cells from a patient that had been immunized with tetanus toxoid were fused with LTR228 lymphoblastoid cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
References: 3570: Raubitschek AR, et al. Human lymphoblastoid cell line and hybridomas derived therefrom. US Patent 4,624,921 dated Nov 25 1986
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG; kappa light chain
ATCC Number：HB-8501?
運(yùn)輸方式：凍存運(yùn)輸
生長狀態(tài)：懸浮生長
是否是腫瘤細(xì)胞：0
物種來源：人
規(guī)格：0.5ml Designations: SA13
Depositors: ?Cetus Corp.
Isotype: IgG; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism:human (B cell); human (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against tetanus toxoid
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 11,12
D16S539: 11,12
D5S818: 12,13
D7S820: 9,10,12
THO1: 8,10,9.3
TPOX: 8,10,11
vWA: 16,17,20
Comments:Peripheral blood B cells from a patient that had been immunized with tetanus toxoid were fused with LTR228 lymphoblastoid cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
References: 3570: Raubitschek AR, et al. Human lymphoblastoid cell line and hybridomas derived therefrom. US Patent 4,624,921 dated Nov 25 1986
